Naringin prevents the structural alterations produced in the small intestine by experimental type 1 Diabetes Mellitus
Diabetic enteropathy is one of the common complications of type 1 Diabetes mellitus (DM1). Naringin (NAR) is a flavonoid with antioxidant, anti-inflammatory and immunomodulatory effects in various tissues. Our objective was to evaluate if NAR prevents the alterations produced in the duodenum,...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Artículo revista |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2022
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/38978 |
| Aporte de: |
| id |
I10-R327-article-38978 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| format |
Artículo revista |
| topic |
diabetes mellitus intestine naringina rats ultraestructure diabetes mellitus intestino naringina ratas ultraestructura |
| spellingShingle |
diabetes mellitus intestine naringina rats ultraestructure diabetes mellitus intestino naringina ratas ultraestructura Talamoni, G Rivoira , MA Collin, A Mukdsi, J Rodríguez, V Naringin prevents the structural alterations produced in the small intestine by experimental type 1 Diabetes Mellitus |
| topic_facet |
diabetes mellitus intestine naringina rats ultraestructure diabetes mellitus intestino naringina ratas ultraestructura |
| author |
Talamoni, G Rivoira , MA Collin, A Mukdsi, J Rodríguez, V |
| author_facet |
Talamoni, G Rivoira , MA Collin, A Mukdsi, J Rodríguez, V |
| author_sort |
Talamoni, G |
| title |
Naringin prevents the structural alterations produced in the small intestine by experimental type 1 Diabetes Mellitus |
| title_short |
Naringin prevents the structural alterations produced in the small intestine by experimental type 1 Diabetes Mellitus |
| title_full |
Naringin prevents the structural alterations produced in the small intestine by experimental type 1 Diabetes Mellitus |
| title_fullStr |
Naringin prevents the structural alterations produced in the small intestine by experimental type 1 Diabetes Mellitus |
| title_full_unstemmed |
Naringin prevents the structural alterations produced in the small intestine by experimental type 1 Diabetes Mellitus |
| title_sort |
naringin prevents the structural alterations produced in the small intestine by experimental type 1 diabetes mellitus |
| description |
Diabetic enteropathy is one of the common complications of type 1 Diabetes mellitus (DM1). Naringin (NAR) is a flavonoid with antioxidant, anti-inflammatory and immunomodulatory effects in various tissues. Our objective was to evaluate if NAR prevents the alterations produced in the duodenum, jejunum and ileum by DM1 at the histological and ultrastructural level.
Two-month-old male Wistar rats were divided into four groups (n=6 for each group): 1) controls, 2) diabetics: rats treated with 60 mg streptozotocin/kg b.w., 3) diabetics treated with NAR40 (40 mg/kg b.w.) 4) diabetics treated with NAR80 (80 mg/kg b.w.). After 30 days treatment, the rats were sacrificed, and the small intestine was removed and weighed. Histological sections of the duodenum, jejunum, and ileum were measured for villus height and width (Image J ProPlus). Ultrastructure was analyzed by transmission electron microscopy. ANOVA/Bonferroni was used for statistical analysis.
The results revealed that diabetic rats had a longer small intestine compared to controls. Treatment with both doses of NAR prevented this increase (Controls:112.27±3.02; STZ:142.71±8.43*; STZ+NAR40:119.13±4.11; STZ+NAR80:116, 85±4.09 cm; *p<0.05 vs controls, STZ+NAR40 and STZ+NAR80). The length and width of the villi of the duodenum were higher in diabetic rats compared to controls, while treatment with NAR80 prevented these alterations (Length: controls: 690.25±35.68; STZ: 849.95 ±30.85*; STZ+NAR40:765.44±26.78; STZ+NAR80:699.20±36.50 µm; *p<0.05 vs controls and STZ+NAR80). The length of the villi of the jejunum and ileum in diabetic rats was higher than that of the control group and treatment with NAR80 normalized this parameter (Controls: 543.85±11.48; STZ: 663.40±20.45*; STZ+NAR40: 559.07±17.25, STZ+NAR80: 535.33±41.42 µm, *p<0.05 vs controls and STZ+NAR80). The ultrastructural study in the duodenum, jejunum and ileum showed marked alterations in diabetic rats with respect to controls, such as widening of the intercellular space and changes in cytoplasmic electron density in some enterocytes. Treatment with both doses of NAR prevented these alterations.
In conclusion, treatment with NAR prevents the structural alterations produced by DM1 in the small intestine, which suggests that this flavonoid is a possible protector of the intestine.
|
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2022 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/38978 |
| work_keys_str_mv |
AT talamonig naringinpreventsthestructuralalterationsproducedinthesmallintestinebyexperimentaltype1diabetesmellitus AT rivoirama naringinpreventsthestructuralalterationsproducedinthesmallintestinebyexperimentaltype1diabetesmellitus AT collina naringinpreventsthestructuralalterationsproducedinthesmallintestinebyexperimentaltype1diabetesmellitus AT mukdsij naringinpreventsthestructuralalterationsproducedinthesmallintestinebyexperimentaltype1diabetesmellitus AT rodriguezv naringinpreventsthestructuralalterationsproducedinthesmallintestinebyexperimentaltype1diabetesmellitus AT talamonig naringinaevitalasalteracionesestructuralesproducidasenelintestinodelgadoporladiabetesmellitustipo1experimental AT rivoirama naringinaevitalasalteracionesestructuralesproducidasenelintestinodelgadoporladiabetesmellitustipo1experimental AT collina naringinaevitalasalteracionesestructuralesproducidasenelintestinodelgadoporladiabetesmellitustipo1experimental AT mukdsij naringinaevitalasalteracionesestructuralesproducidasenelintestinodelgadoporladiabetesmellitustipo1experimental AT rodriguezv naringinaevitalasalteracionesestructuralesproducidasenelintestinodelgadoporladiabetesmellitustipo1experimental |
| first_indexed |
2024-09-03T21:03:51Z |
| last_indexed |
2024-09-03T21:03:51Z |
| _version_ |
1809210337182875648 |
| spelling |
I10-R327-article-389782024-04-15T16:14:45Z Naringin prevents the structural alterations produced in the small intestine by experimental type 1 Diabetes Mellitus Naringina evita las alteraciones estructurales producidas en el intestino delgado por la Diabetes mellitus tipo 1 experimental Talamoni, G Rivoira , MA Collin, A Mukdsi, J Rodríguez, V diabetes mellitus intestine naringina rats ultraestructure diabetes mellitus intestino naringina ratas ultraestructura Diabetic enteropathy is one of the common complications of type 1 Diabetes mellitus (DM1). Naringin (NAR) is a flavonoid with antioxidant, anti-inflammatory and immunomodulatory effects in various tissues. Our objective was to evaluate if NAR prevents the alterations produced in the duodenum, jejunum and ileum by DM1 at the histological and ultrastructural level. Two-month-old male Wistar rats were divided into four groups (n=6 for each group): 1) controls, 2) diabetics: rats treated with 60 mg streptozotocin/kg b.w., 3) diabetics treated with NAR40 (40 mg/kg b.w.) 4) diabetics treated with NAR80 (80 mg/kg b.w.). After 30 days treatment, the rats were sacrificed, and the small intestine was removed and weighed. Histological sections of the duodenum, jejunum, and ileum were measured for villus height and width (Image J ProPlus). Ultrastructure was analyzed by transmission electron microscopy. ANOVA/Bonferroni was used for statistical analysis. The results revealed that diabetic rats had a longer small intestine compared to controls. Treatment with both doses of NAR prevented this increase (Controls:112.27±3.02; STZ:142.71±8.43*; STZ+NAR40:119.13±4.11; STZ+NAR80:116, 85±4.09 cm; *p<0.05 vs controls, STZ+NAR40 and STZ+NAR80). The length and width of the villi of the duodenum were higher in diabetic rats compared to controls, while treatment with NAR80 prevented these alterations (Length: controls: 690.25±35.68; STZ: 849.95 ±30.85*; STZ+NAR40:765.44±26.78; STZ+NAR80:699.20±36.50 µm; *p<0.05 vs controls and STZ+NAR80). The length of the villi of the jejunum and ileum in diabetic rats was higher than that of the control group and treatment with NAR80 normalized this parameter (Controls: 543.85±11.48; STZ: 663.40±20.45*; STZ+NAR40: 559.07±17.25, STZ+NAR80: 535.33±41.42 µm, *p<0.05 vs controls and STZ+NAR80). The ultrastructural study in the duodenum, jejunum and ileum showed marked alterations in diabetic rats with respect to controls, such as widening of the intercellular space and changes in cytoplasmic electron density in some enterocytes. Treatment with both doses of NAR prevented these alterations. In conclusion, treatment with NAR prevents the structural alterations produced by DM1 in the small intestine, which suggests that this flavonoid is a possible protector of the intestine. La enteropatía diabética es una de las complicaciones comunes de la Diabetes mellitus tipo 1 (DM1). Naringina (NAR) es un flavonoide con efectos antioxidantes, antiinflamatorios e inmunomoduladores en diversos tejidos. El objetivo de este trabajo fue evaluar si NAR evita las alteraciones producidas en duodeno, yeyuno e ileon por la DM1 a nivel histológico y ultraestructural. Se utilizaron ratas Wistar machos de 2 meses de edad (n=6 por cada grupo): 1) controles, 2) diabéticas: inducidas con 60 mg de estreptozotocina (STZ)/kg de p.c., 3) diabéticas tratadas con NAR40 (40 mg/kg de p.c.) 4) diabéticas tratadas con NAR80 (80 mg/kg de p.c). Después de 30 días de tratamiento las ratas se sacrificaron y se removió y pesó el intestino delgado. En secciones histológicas de duodeno, yeyuno e ileon se midieron la altura y el ancho de las vellosidades (Image JProPlus). La ultraestructura se analizó por microscopía electrónica de trasmisión. Se empleó ANOVA/Bonferroni para análisis estadístico. Los resultados revelaron que las ratas diabéticas presentaron mayor largo del intestino delgado en comparación con el de los controles. El tratamiento con ambas dosis de NAR evitó dicho aumento (Controles:112,27±3,02; STZ:142,71±8,43*; STZ+NAR40:119,13±4,11; STZ+NAR80:116,85±4,09 cm; *p<0,05 vs controles, STZ+NAR40 y STZ+NAR80). La longitud y ancho de las vellosidades del duodeno fueron mayores en las ratas diabéticas en comparación con el de los controles, mientras que el tratamiento con NAR80 evitó esas alteraciones (Longitud: controles:690,25±35,68; STZ:849,95±30,85*; STZ+NAR40:765,44±26,78; STZ+NAR80:699,20±36,50 µm; *p<0,05 vs controles y STZ+NAR80). El largo de las vellosidades del yeyuno e íleon en las ratas diabéticas fue mayor que los del grupo control y el tratamiento con NAR80 normalizó ese parámetro (Controles:543,85±11,48; STZ:663,40±20,45*; STZ+NAR40:559,07±17,25; STZ+NAR80:535,33±41,42 µm; *p<0,05 vs controles y STZ+NAR80). El estudio ultraestructural en duodeno, yeyuno e íleon evidenció marcadas alteraciones en las ratas diabéticas con respecto a los controles como ampliación del espacio intercelular y cambios en la electrodensidad citoplasmática en algunos enterocitos. El tratamiento con ambas dosis de NAR previno dichas alteraciones. En conclusión, el tratamiento con NAR evita las alteraciones estructurales producidas por la DM1 en el intestino delgado, lo que sugiere que este flavonoide es un posible protector del intestino. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2022-10-26 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion texto https://revistas.unc.edu.ar/index.php/med/article/view/38978 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 79 No. Suplemento JIC XXIII (2022): Suplemento JIC XXIII Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 79 Núm. Suplemento JIC XXIII (2022): Suplemento JIC XXIII Revista da Faculdade de Ciências Médicas de Córdoba; v. 79 n. Suplemento JIC XXIII (2022): Suplemento JIC XXIII 1853-0605 0014-6722 Derechos de autor 2022 Universidad Nacional de Córdoba http://creativecommons.org/licenses/by-nc/4.0 |